CliffBio
small molecule

DIAZEPAM

DIAZEPAM

Loss of exclusivity—loss of exclusivity
CompanyLong Grove →See this company's full patent-cliff portfolio

Drug detail

Brand nameDIAZEPAM
Active ingredientDIAZEPAM
Strength10MG/2ML (5MG/ML)
Dosage formINJECTABLE
RouteINJECTION
ModalitySmall molecule
FDA approvalDecember 2024
Marketing statusRX

More from Long Grove

Source: FDA Orange Book, layered on the CliffBio company graph. Cliff dates are the loss of exclusivity; estimates are projections, not legal advice.

DIAZEPAM patent cliff — loss of exclusivity — | CliffBio